ATE258789T1 - 5-ht2-antagonisten in der behandlung venöser zustände - Google Patents

5-ht2-antagonisten in der behandlung venöser zustände

Info

Publication number
ATE258789T1
ATE258789T1 AT93906979T AT93906979T ATE258789T1 AT E258789 T1 ATE258789 T1 AT E258789T1 AT 93906979 T AT93906979 T AT 93906979T AT 93906979 T AT93906979 T AT 93906979T AT E258789 T1 ATE258789 T1 AT E258789T1
Authority
AT
Austria
Prior art keywords
treatment
antagonists
venous
venous conditions
conditions
Prior art date
Application number
AT93906979T
Other languages
English (en)
Inventor
M Samir Amer
Original Assignee
Sam Amer & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sam Amer & Co Inc filed Critical Sam Amer & Co Inc
Application granted granted Critical
Publication of ATE258789T1 publication Critical patent/ATE258789T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AT93906979T 1992-01-09 1993-02-19 5-ht2-antagonisten in der behandlung venöser zustände ATE258789T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/818,389 US5266571A (en) 1992-01-09 1992-01-09 Treatment of hemorrhoids with 5-HT2 antagonists
PCT/US1993/001485 WO1994018958A1 (en) 1992-01-09 1993-02-19 5-ht2 receptor antagonist compositions useful in treating venous conditions

Publications (1)

Publication Number Publication Date
ATE258789T1 true ATE258789T1 (de) 2004-02-15

Family

ID=25225434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93906979T ATE258789T1 (de) 1992-01-09 1993-02-19 5-ht2-antagonisten in der behandlung venöser zustände

Country Status (11)

Country Link
US (2) US5266571A (de)
EP (1) EP0684816B1 (de)
KR (1) KR100278522B1 (de)
AT (1) ATE258789T1 (de)
AU (1) AU678149B2 (de)
CA (1) CA2156481C (de)
DE (1) DE69333413T2 (de)
DK (1) DK0684816T3 (de)
ES (1) ES2215990T3 (de)
PT (1) PT684816E (de)
WO (1) WO1994018958A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5780487A (en) * 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
DE10025644A1 (de) * 2000-05-24 2001-12-06 Lohmann Therapie Syst Lts Schmales bandförmiges transdermales therapeutisches System zur Applikation von Wirkstoffen direkt über dem arteriellen oder venösen Gefäßsystem
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
US20050107867A1 (en) * 2003-11-17 2005-05-19 Taheri Syde A. Temporary absorbable venous occlusive stent and superficial vein treatment method
US7402320B2 (en) * 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
US7972354B2 (en) * 2005-01-25 2011-07-05 Tyco Healthcare Group Lp Method and apparatus for impeding migration of an implanted occlusive structure
US20070082076A1 (en) * 2005-10-12 2007-04-12 Spencer Feldman Glutathione and coffee suppository
US9017361B2 (en) * 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
CN108440520A (zh) * 2018-03-12 2018-08-24 首都医科大学 苯并异噻唑类化合物及其制备方法和在治疗抑郁症方面的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000143A (en) * 1971-03-03 1976-12-28 Mead Johnson & Company Substituted piperidines
US4064254A (en) * 1971-03-03 1977-12-20 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
USRE30812E (en) * 1971-03-03 1981-12-01 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
USRE30811E (en) * 1971-03-03 1981-12-01 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
US3931195A (en) * 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
ES456574A1 (es) * 1977-03-07 1978-02-16 Rocador Sa Procedimiento de obtencion de pentametil-carbamato de quer- cetina.
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4265887A (en) * 1979-12-11 1981-05-05 Breskman Joseph S Composition and method for treatment of hemorrhoids
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4539318A (en) * 1984-06-04 1985-09-03 Merck & Co., Inc. Tertiary aminohydroxypropoxy substituted thiadiazoles, pharmaceutical compositions and use
US4665075A (en) * 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
CA1246074A (en) * 1984-12-05 1988-12-06 Albertus H.M.T. Van Heertum Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4677104A (en) * 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
US4626433A (en) * 1985-05-20 1986-12-02 Preparation Gold, Inc. Remedy for hemorrhoids
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5196405A (en) * 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
IT8947616A0 (it) * 1989-02-06 1989-02-06 Verde Giancarlo Umberto Preparato per il trattamento e la cura delle emorroidi
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
DE69327432T2 (de) * 1992-02-07 2000-05-18 Kaken Pharma Co Ltd Heilmittel für wunden und hämorrhoiden

Also Published As

Publication number Publication date
AU3774893A (en) 1994-09-14
WO1994018958A1 (en) 1994-09-01
US5266571A (en) 1993-11-30
DK0684816T3 (da) 2004-06-14
DE69333413T2 (de) 2004-12-02
KR960700696A (ko) 1996-02-24
PT684816E (pt) 2004-06-30
ES2215990T3 (es) 2004-10-16
CA2156481A1 (en) 1994-09-01
AU678149B2 (en) 1997-05-22
EP0684816A1 (de) 1995-12-06
CA2156481C (en) 2004-05-11
US5605902A (en) 1997-02-25
DE69333413D1 (de) 2004-03-11
KR100278522B1 (ko) 2001-01-15
EP0684816B1 (de) 2004-02-04

Similar Documents

Publication Publication Date Title
ATE258789T1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
DK0882021T3 (da) Nye phenanthridiner
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
CY1113841T1 (el) Μεθοδος και συνθεση για την θεραπεια ουλων
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DK0889886T3 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ATE169445T1 (de) Verwendung von gelformulierungen als beizmittel
DE3888994T2 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
NO964238D0 (no) Halofantrin-fri-base for behandling av malaria og blandinger
DE69110713T2 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE111081T1 (de) Disubstituierte pyridine.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE69705110T2 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
DE336374T1 (de) Behandlung von zusammensetzungen von polyimid-vorlaeufern.
IT8222911A0 (it) Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0684816

Country of ref document: EP